Synonym
Cidofovir sodium; Cidofovir disodium; UNII-M83JB37U61; GS-504; GS 504; GS504; GS-0504; GS 0504; GS0504;
IUPAC/Chemical Name
sodium (S)-(((1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonate
InChi Key
HKIAHFPOQYDOHP-ILKKLZGPSA-L
InChi Code
InChI=1S/C8H14N3O6P.2Na/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16;;/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16);;/q;2*+1/p-2/t6-;;/m0../s1
SMILES Code
NC1=NC(N(C=C1)C[C@H](OCP([O-])([O-])=O)CO)=O.[Na+].[Na+]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
323.15
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ison MG, Hayden RT. Adenovirus. Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.DMIH2-0020-2015. PMID: 27726766.
2: Alcamo AM, Wolf MS, Alessi LJ, Chong HJ, Green M, Williams JV, Simon DW. Successful Use of Cidofovir in an Immunocompetent Child With Severe Adenoviral Sepsis. Pediatrics. 2020 Jan;145(1):e20191632. doi: 10.1542/peds.2019-1632. Epub 2019 Dec 11. PMID: 31826930; PMCID: PMC6939840.
3: Lynch JP 3rd, Fishbein M, Echavarria M. Adenovirus. Semin Respir Crit Care Med. 2011 Aug;32(4):494-511. doi: 10.1055/s-0031-1283287. Epub 2011 Aug 19. PMID: 21858752.
4: Lynch JP 3rd, Kajon AE. Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention. Semin Respir Crit Care Med. 2016 Aug;37(4):586-602. doi: 10.1055/s-0036-1584923. Epub 2016 Aug 3. PMID: 27486739; PMCID: PMC7171713.
5: Meesing A, Razonable RR. New Developments in the Management of Cytomegalovirus Infection After Transplantation. Drugs. 2018 Jul;78(11):1085-1103. doi: 10.1007/s40265-018-0943-1. PMID: 29961185.
6: Mühlbacher T, Beck R, Nadalin S, Heyne N, Guthoff M. Low-dose cidofovir and conversion to mTOR-based immunosuppression in polyomavirus-associated nephropathy. Transpl Infect Dis. 2020 Apr;22(2):e13228. doi: 10.1111/tid.13228. Epub 2019 Dec 16. PMID: 31797495.
7: Nickles MA, Sergeyenko A, Bain M. Treatment of warts with topical cidofovir in a pediatric patient. Dermatol Online J. 2019 May 15;25(5):13030/qt5sq5b24g. PMID: 31220896.
8: Greeley ZW, Giannasca NJ, Porter MJ, Margulies BJ. Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus TYPE 1. Antiviral Res. 2020 Apr;176:104754. doi: 10.1016/j.antiviral.2020.104754. Epub 2020 Feb 27. PMID: 32114034.
9: Lea AP, Bryson HM. Cidofovir. Drugs. 1996 Aug;52(2):225-230; discussion 231. doi: 10.2165/00003495-199652020-00006. PMID: 8841740.
10: Gerna G, Lilleri D, Baldanti F. An overview of letermovir: a cytomegalovirus prophylactic option. Expert Opin Pharmacother. 2019 Aug;20(12):1429-1438. doi: 10.1080/14656566.2019.1637418. Epub 2019 Jul 8. PMID: 31282759.
